montelukast


Also found in: Medical, Wikipedia.
Related to montelukast: Montelukast sodium, Singulair

mon·te·lu·kast

 (mŏn′tə-lo͞o′kăst)
n.
A drug that reduces the inflammatory response by acting as a leukotriene receptor antagonist, and is used to treat the signs and symptoms of asthma.

[monte-, of unknown origin + -lukast, leukotriene receptor antagonist suff.; see zafirlukast.]
Translations

montelukast

n montelukast m
References in periodicals archive ?
Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD4 in asthmatics.
Greenstone LLC has added montelukast sodium tablets and chewable tablets to its portfolio of generic pharmaceuticals.
Reddya[euro](tm)s Laboratories unveils FDA approved Montelukast Sodium Tablets and Montelukast Sodium Chewable Tablets in the US(C)2012 M2 COMMUNICATIONS
The addition of fluticasone nasal spray or montelukast significantly reduced nasal symptoms, compared with placebo, but it had no effect on asthma symptoms (Chest 2005;128:1910-20).
A third group of patients did not fare as well on a pill containing 5 mg or 10 mg of montelukast each day.
A recent study assessed the effects of montelukast (Singulair) on 64 children with exercise-induced bronchoconstriction.
Those are the key conclusions of a study that sought to determine whether responses to fluticasone and montelukast are the same for all children with asthma or whether some pediatric patients who do not respond to one medication may respond to the other.
CHICAGO -- The rate of congenital anomalies associated with montelukast use during pregnancy does not differ from the background rate, according to pregnancy registry data.
contract awarded for:quotations for the supply of montelukast 5mg chewable tablets
In the bulk drugs category, Montelukast recorded highest growth of 25 per cent in its sales numbers at Rs.
M2 EQUITYBITES-December 18, 2017-IntelGenx Corp receives approval from Health Canada for clinical trial application for Montelukast VersaFilm
M2 PHARMA-December 18, 2017-IntelGenx Corp receives approval from Health Canada for clinical trial application for Montelukast VersaFilm